Collaboration and License Agreements - Additional Information (Details) $ in Thousands		3 Months Ended		6 Months Ended
	Mar. 31, 2020 USD ($) Target	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)
Collaboration And License Agreements [Line Items]
Collaboration and license revenue		$ 2,848		$ 4,875
Incurred costs		13,527	$ 5,616	23,472	$ 11,252
Deferred revenue, current portion		11,746		$ 11,746		$ 10,627
Novartis
Collaboration And License Agreements [Line Items]
License agreement date	Mar. 31, 2020
Upfront payment received	$ 20,000
Collaborations and license agreements, expected milestone receivable	$ 10,000
Collaboration period				180 days
Negotiation period				180-day
Expects research term	3 years
Revenue recognition milestone method milestone payables	$ 20,000
Estimated research costs transaction price	$ 10,000
Collaboration and license revenue				$ 4,700
Incurred costs				700
Deferred revenue, current portion		11,700		11,700
Long-term deferred revenue		$ 4,600		$ 4,600
Novartis | Maximum
Collaboration And License Agreements [Line Items]
Number of targets identified | Target	3